Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide With or Without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM)

X
Trial Profile

A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide With or Without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM)

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 15 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Elotuzumab (Primary) ; Bortezomib; Bortezomib; Dexamethasone; Dexamethasone; Lenalidomide
  • Indications Multiple myeloma; Plasma cell leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Dec 2023 Results (n=541) of a secondary post-hoc analysis of SWOG Studies S0777 and S1211 assessing impact of Dexamethasone dose reductions on post-induction outcomes in subset of patients who completed all eight 3-week cycles of induction presented at the 65th American Society of Hematology Annual Meeting and Exposition
    • 17 Jun 2022 Results presented at the 27th Congress of the European Haematology Association
    • 07 Jun 2022 Primary endpoint has not been met (Progression-free Survival), as per Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top